Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that it has dosed the first patient in its pivotal Phase III grass allergy trial. This international trial will be undertaken at approximately 96 centres in 4 countries and will involve enrolment of over 1000 patients. The majority of patients will be recruited in the United States.
